首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Anti-cancer Drugs

Anti-cancer Drugs杂志,由Lippincott Williams and Wilkins Ltd.出版,于1990年创刊,Monthly,出版语言English,ISSN:0959-4973,E-ISSN:1473-5741。

投稿咨询
Anti-cancer Drugs
Anti-cancer Drugs
Anti-cancer Drugs
SCI SCIE

杂志介绍

JCR分区
Q3
中科院分区
4区
影响因子
2
CiteScore
4.6
期刊收录
SCI、SCIE

Anti-cancer Drugs(中文译名:《抗癌药》),ISSN:0959-4973,EISSN:1473-5741,是Lippincott Williams and Wilkins Ltd.出版的国际性学术期刊,创刊于1990年,以Monthly形式稳定发行,2026年总发文量约103篇。该刊采用非OA开放访问,学科归属为医学 - 药学。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达2,2025年期刊CiteScore为4.6,2025年期刊自引率约0%,在中科院期刊分区体系中位列医学大类4区,在所属学科领域具备高学术影响力与国际认可度。Anti-cancer Drugs长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期偏慢,4-8周,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,CHINA MAINLANDItaly、USA、Japan、GERMANY (FED REP GER)、France、Brazil等为核心发文国家与地区;ZHENGZHOU UNIVERSITYNANJING MEDICAL UNIVERSITY、UNIVERSITY OF BOLOGNA、SHANDONG FIRST MEDICAL UNIVERSITY & SHANDONG ACADEMY OF MEDICAL SCIENCES、SHANDONG UNIVERSITY、SUZHOU UNIVERSITY、CHINESE ACADEMY OF SCIENCES等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
4区
ONCOLOGY 肿瘤学 PHARMACOLOGY & PHARMACY 药学
4区 4区

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
4区
ONCOLOGY 肿瘤学 PHARMACOLOGY & PHARMACY 药学
4区 4区

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
4区
ONCOLOGY 肿瘤学 PHARMACOLOGY & PHARMACY 药学
4区 4区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q4 250 / 333

25.1

学科:PHARMACOLOGY & PHARMACY SCIE Q3 249 / 356

30.2

学科:ONCOLOGY SCIE Q3 196 / 333

41.29

学科:PHARMACOLOGY & PHARMACY SCIE Q3 207 / 356

41.99

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q3 217 / 328

34

学科:PHARMACOLOGY & PHARMACY SCIE Q3 209 / 352

40.8

学科:ONCOLOGY SCIE Q3 184 / 328

44.05

学科:PHARMACOLOGY & PHARMACY SCIE Q3 202 / 353

42.92


中国学者近期发文

1
Interferon regulatory factor 4 drives M2 macrophage polarization in lung adenocarcinoma via the absent in melanoma 2-mediated phosphoinositide 3-kinase/protein kinase B signaling pathwa

Author:Zou, Xiaoyun; Ji, Qing; Wen, Zhongzheng; Lei, Limei; Chen, Xuan; Hu, Wen

Journal: ANTI-CANCER DRUGS. 2026; Vol. 37, Issue 5, pp. 343-351. DOI: 10.1097/CAD.0000000000001795

2
Eugenol as a game-changer: overcoming osimertinib resistance in non-small cell lung cancer by inhibiting glycolysis via the tripartite motif containing 59/extracellular signal-regulated kinase pathwa

Author:Zhao, Kun; Wang, Wei; Sun, Yansha; Li, Ke

Journal: ANTI-CANCER DRUGS. 2026; Vol. 37, Issue 5, pp. 312-328. DOI: 10.1097/CAD.0000000000001793

3
Hematopoietic progenitor kinase 1 inhibitor BGB-15025 induces apoptosis in acute myeloid leukemia cells through the cell cycle pathway and mitogen-activated protein kinase/extracellular signal-regulated kinase pathway signaling axi

Author:Yang, Shiyu; Li, Fenglin; Zhuang, Haihui; Chen, Dong; Jiang, Xia; Zhou, Yanhan; Pei, Renzhi; Li, Shuangyue; Ye, Peipei; Lu, Ying

Journal: ANTI-CANCER DRUGS. 2026; Vol. 37, Issue 5, pp. 329-342. DOI: 10.1097/CAD.0000000000001794

4
Treatment of HRD-positive elderly ovarian cancer patient: a case repor

Author:Jiang, Yuxin; Yi, Qijun; Wang, Yueer; Li, Chen; Liu, Haiyan

Journal: ANTI-CANCER DRUGS. 2026; Vol. 37, Issue 5, pp. 352-357. DOI: 10.1097/CAD.0000000000001772

5
Inhibiting FGFR by toadflax reverses erlotinib resistance in nonsmall cell lung cance

Author:Han, Bateer; Ma, Ying; Bao, Shuguang; Gao, Hui; Gao, Yanqing; Guo, Qiang; Li, Ao; Li, Meitao; Yu, Rong; Wang, Hongwei

Journal: ANTI-CANCER DRUGS. 2026; Vol. 37, Issue 5, pp. 301-311. DOI: 10.1097/CAD.0000000000001649

6
Multimodal treatment with thiotepa, bevacizumab, teniposide, and tunlametinib in a patient with neurofibromatosis type 1-associated oligodendroglioma: a rare case repor

Author:Zhou, Shizhen; Chen, Yanfei; Gao, Guoliang; Pan, Xueqiang; Sun, Peng; Tao, Rongjie

Journal: ANTI-CANCER DRUGS. 2026; Vol. 37, Issue 4, pp. -. DOI: 10.1097/CAD.0000000000001786

7
Comparative efficacy and safety of S-1 plus oxaliplatin with sintilimab vs. paclitaxel-S-1-oxaliplatin and docetaxel-oxaliplatin-5-fluorouracil as first-line therapy for advanced gastric cance

Author:Wang, Yicong; Ma, Bingyang; Zhang, Chenguang; Wang, Yuwen; Pan, Ting; Zhao, Chunlong; Cai, Baojia; Yu, Pengjie; Guo, Bin; Ma, Jinfu

Journal: ANTI-CANCER DRUGS. 2026; Vol. 37, Issue 4, pp. 253-264. DOI: 10.1097/CAD.0000000000001782

8
EP4 influences bortezomib resistance in multiple myeloma by modulating endoplasmic reticulum stress via the phosphatidylinositol 3-kinase/protein kinase B pathwa

Author:Shi, Tengfei; Chen, Yao; Liu, Zhiqiang; Liu, Aichun

Journal: ANTI-CANCER DRUGS. 2026; Vol. 37, Issue 4, pp. 280-296. DOI: 10.1097/CAD.0000000000001792

9
Initial stage analysis of tislelizumab in combination with chemotherapy for patients with advanced HIV-positive non-small-cell lung cancer: a comparative clinical tria

Author:Quan, Yaping; Li, Hao; Liang, Zhengjie; Shen, Jie; Hu, Yong

Journal: ANTI-CANCER DRUGS. 2026; Vol. 37, Issue 4, pp. 272-279. DOI: 10.1097/CAD.0000000000001784

10
Identification of uridine phosphatase 1 as a potential therapeutic target in gastric cancer by integrated bioinformatics analysis and experimental validatio

Author:Wang, Yongfeng; Feng, Yichen; Zhu, Chengzhang; Guan, Ling; Wang, Shengfeng; Zou, Anqi; Yu, Miao; Yuan, Yuan; Cai, Hui

Journal: ANTI-CANCER DRUGS. 2026; Vol. 37, Issue 3, pp. 217-237. DOI: 10.1097/CAD.0000000000001745


在线咨询

Anti-cancer Drugs

国际简称:ANTI-CANCER DRUG参考译名:抗癌药

年发文量:103 CiteScore:4.6 是否预警:否 Gold OA文章占比:27.32% 研究类文章占比:100.00%

杂志社联系方式:LIPPINCOTT WILLIAMS & WILKINS, 530 WALNUT ST, PHILADELPHIA, USA, PA, 19106-3621

Anti-cancer Drugs